ArticleMaterials today. Bio2025
Surface bio-engineering of melt electrowritten tubular scaffolds via plasma immersion ion implantation (PIII).
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomolecule-functionalized dental implant surfaces: Towards augmenting soft tissue integration.Bioactive materials · 2025Review
- Heparin-Based Growth Factor Delivery Platforms: A Review.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melt electrowriting (MEW) enables the fabrication of highly controlled, open-pore tubular constructs for replicating the complex architectures of vascular, renal, and other tissues. However, a key challenge is to functionalize their surfaces so that they not only support but also instruct key biological interactions, particularly in promoting vascularization. Here, we propose plasma immersion ion implantation (PIII) as a biofunctionalization strategy for open-pore tubular constructs fabricated by MEW. Surface chemistry analysis confirmed homogeneous treatment across PIII-treated MEW 3D structures, while uniaxial tensile tests demonstrated no significant changes in mechanical properties following the treatment. Electron paramagnetic resonance (EPR) data provided evidence of the formation of a stable, radical-rich surface, which was further validated by fluorescence imaging with a model molecule, confirming the radicals' role in enabling uniform covalent biomolecule attachment. The PIII-treated MEW constructs were covalently functionalized with vascular endothelial growth factor (VEGF), thereby modulating the behavior of seeded cells. Endothelialization studies using conditionally immortalized glomerular endothelial cells (ciGEnC) demonstrated that VEGF-immobilized MEW tubes effectively support monolayer formation, achieving outcomes comparable to those observed with VEGF supplementation in culture media. Remarkably, the immobilized VEGF sustained endothelialization with a similar effectiveness to traditional VEGF suspension methods over prolonged culture conditions (21 days), but without the need for continuous VEGF supplementation. These findings establish a novel biofunctionalization strategy for vascularized tissue engineering scaffolds and pave the way for plasma-modified MEW tubes as platforms for preclinical models and regenerative medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.